2065 related articles for article (PubMed ID: 32145830)
1. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
9. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
11. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
12. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
[TBL] [Abstract][Full Text] [Related]
15. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials.
Hoffmann-Vold AM; Volkmann ER; Allanore Y; Assassi S; de Vries-Bouwstra JK; Smith V; Tschoepe I; Loaiza L; Kanakapura M; Distler O
Lancet Rheumatol; 2022 Oct; 4(10):e679-e687. PubMed ID: 38265966
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
[TBL] [Abstract][Full Text] [Related]
19. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics.
Kolb M; Flaherty KR; Silva RS; Prasse A; Vancheri C; Mueller H; Sroka-Saidi K; Wells AU;
Adv Ther; 2023 Dec; 40(12):5536-5546. PubMed ID: 37751022
[TBL] [Abstract][Full Text] [Related]
20. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]